Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Por van der Veldt, A A M, Boven, E, van den Eertwegh, A J M, Haanen, J B A G
Publicado em 2009

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

Por van der Veldt, A A M, Meijerink, M R, van den Eertwegh, A J M, Haanen, J B A G, Boven, E
Publicado em 2010

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

Por De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., Uyl-de Groot, C. A.
Publicado no BMC Cancer (2016)

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma

Por Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Dellemijn, T A M, van den Bogaard, C, Nooijen, W J, de Gast, G C, Haanen, J B A G, Bex, A
Publicado em 2010

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Por van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Publicado em 2008

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

Por Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Publicado em 2014